CUE CUE BIOPHARMA INC revenue, earnings and financials
For the quarter ended June 30, 2026, CUE BIOPHARMA INC reported revenue of $7.88M (up 166.7% from a year earlier), net income of −$153M and diluted EPS of −$24.14; over the last four quarters revenue was $37.7M and net income −$164M; for the fiscal year ended December 2025 revenue was $27.5M, up 195.7% on the year before.
CUE annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $27.5M, gross profit n/a, operating income −$26.6M, net income −$26.6M (margin -96.9%), EPS −$0.28
- Fiscal year ended Dec 2024: revenue $9.29M, gross profit n/a, operating income −$41.5M, net income −$40.7M (margin -438.0%), EPS −$0.72
- Fiscal year ended Dec 2023: revenue $5.49M, gross profit n/a, operating income −$52.1M, net income −$50.7M (margin -924.1%), EPS −$1.11
- Fiscal year ended Dec 2022: revenue $1.25M, gross profit n/a, operating income −$53.2M, net income −$53.0M (margin -4257.8%), EPS −$1.49
- Fiscal year ended Dec 2021: revenue $14.9M, gross profit n/a, operating income −$43.7M, net income −$44.2M (margin -295.6%), EPS −$1.41
CUE quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $7.88M (up 166.7% year over year), net income −$153M, EPS −$24.14
- Quarter ended Mar 31, 2026: revenue $5.69M (up 1250.6% year over year), net income −$5.18M, EPS −$1.08
- Quarter ended Dec 31, 2025 (from the annual report): revenue $21.9M (up 1292.3% year over year), net income $1.59M, EPS $7.41
- Quarter ended Sep 30, 2025: revenue $2.15M (down 35.6% year over year), net income −$7.45M, EPS −$0.07
- Quarter ended Jun 30, 2025: revenue $2.95M (up 11.1% year over year), net income −$8.48M, EPS −$2.67
- Quarter ended Mar 31, 2025: revenue $421K (down 75.5% year over year), net income −$12.3M, EPS −$4.95
- Quarter ended Dec 31, 2024 (from the annual report): revenue $1.58M (down 13.5% year over year), net income −$9.50M, EPS −$0.10
- Quarter ended Sep 30, 2024: revenue $3.34M (up 58.9% year over year), net income −$8.66M, EPS −$0.17
- Quarter ended Jun 30, 2024: revenue $2.66M (up 92.3% year over year), net income −$10.2M, EPS −$0.20
- Quarter ended Mar 31, 2024: revenue $1.72M (up 818.2% year over year), net income −$12.3M, EPS −$0.25
- Quarter ended Dec 31, 2023 (from the annual report): revenue $1.82M (up 1106.0% year over year), net income −$13.4M, EPS −$0.29
- Quarter ended Sep 30, 2023: revenue $2.10M (up 2988.2% year over year), net income −$11.0M, EPS −$0.24
- Quarter ended Jun 30, 2023: revenue $1.38M (up 5215.4% year over year), net income −$13.2M, EPS −$0.29
- Quarter ended Mar 31, 2023: revenue $187K (down 81.3% year over year), net income −$13.1M, EPS −$0.29
- Quarter ended Dec 31, 2022 (from the annual report): revenue $151K (down 98.2% year over year), net income −$14.6M, EPS −$0.37
- Quarter ended Sep 30, 2022: revenue $68.0K (down 97.2% year over year), net income −$11.0M, EPS −$0.31
- Quarter ended Jun 30, 2022: revenue $26.0K (down 99.1% year over year), net income −$13.2M, EPS −$0.37
- Quarter ended Mar 31, 2022: revenue $1.00M (down 35.6% year over year), net income −$14.3M, EPS −$0.44
- Quarter ended Dec 31, 2021 (from the annual report): revenue $8.25M, net income −$8.38M, EPS −$0.26
- Quarter ended Sep 30, 2021: revenue $2.40M, net income −$13.0M, EPS −$0.41
CUE cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$21.7M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$36.3M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$40.0M, share buybacks $0
- Fiscal year ended Dec 2022: operating cash flow −$41.8M, share buybacks $200K
- Fiscal year ended Dec 2021: operating cash flow −$38.8M, share buybacks $750K
CUE balance sheet
- Jun 30, 2026: cash $17.4M, total assets $30.7M, total liabilities $28.4M, shareholders' equity $2.31M
- Mar 31, 2026: cash $16.4M, total assets $30.9M, total liabilities $9.27M, shareholders' equity $21.6M
- Dec 31, 2025: cash $27.1M, total assets $42.2M, total liabilities $15.8M, shareholders' equity $26.4M
- Sep 30, 2025: cash $11.7M, total assets $31.6M, total liabilities $18.4M, shareholders' equity $13.2M
- Jun 30, 2025: cash $27.5M, total assets $40.7M, total liabilities $22.5M, shareholders' equity $18.2M
- Mar 31, 2025: cash $13.1M, total assets $22.3M, total liabilities $15.7M, shareholders' equity $6.58M
- Dec 31, 2024: cash $22.5M, total assets $32.2M, total liabilities $14.7M, shareholders' equity $17.5M, long-term debt $0
- Sep 30, 2024: cash $32.4M, total assets $44.8M, total liabilities $19.4M, shareholders' equity $25.4M, long-term debt $1.33M
What is CUE's revenue?
CUE BIOPHARMA INC reported $37.7M of revenue over its last four quarters, through June 30, 2026.
Is CUE profitable?
No. CUE BIOPHARMA INC lost $164M over the last four quarters.
What is CUE's EPS?
Diluted earnings per share over the last four quarters were −$17.88; −$24.14 in the latest quarter.